Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)

Value Set ◽

PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN

Value in Health ◽

10.1016/j.jval.2019.09.409 ◽

2019 ◽

Vol 22 ◽

pp. S477

Author(s):

S. Taheri ◽

Z. Karimi Majd ◽

N. Yousefi ◽

F. Peiravian

Keyword(s):

Prostate Cancer ◽

Supportive Care ◽

Best Supportive Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Multicenter, Randomized, Double-Blind Phase Ii Study of Sorafenib Compared to Placebo with Best Supportive Care After Failure of Docetaxel in Metastatic Castration-Resistant Prostate Cancer

Annals of Oncology ◽

10.1093/annonc/mdu336.21 ◽

2014 ◽

Vol 25 ◽

pp. iv266

Author(s):

G. Kramer ◽

A. Maj-Hes ◽

A. Hobisch ◽

S.F. Shariat ◽

W. Loidl

Keyword(s):

Prostate Cancer ◽

Supportive Care ◽

Phase Ii ◽

Phase Ii Study ◽

Best Supportive Care ◽

Double Blind ◽

Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt)

Value in Health ◽

10.1016/j.jval.2015.09.1266 ◽

2015 ◽

Vol 18 (7) ◽

pp. A474

Author(s):

C Vicente ◽

A Loblaw ◽

S North ◽

W Kassouf ◽

S Naidoo ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Androgen Deprivation ◽

Utility Analysis ◽

PCN129 A COST-UTILITY AND BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR THE TREATMENT OF NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) IN MEXICO

Value in Health ◽

10.1016/j.jval.2020.04.1619 ◽

2020 ◽

Vol 23 ◽

pp. S45-S46

Author(s):

W. Toro ◽

S. Braun ◽

L.A. Sanchez ◽

P. Anaya

Keyword(s):

Prostate Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Cost Utility ◽

Budget Impact Analysis ◽

Cost-Utility Analysis of Enzalutamide for Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer (MCRPC)

Value in Health ◽

10.1016/j.jval.2014.03.521 ◽

2014 ◽

Vol 17 (3) ◽

pp. A89-A90 ◽

Cited By ~ 1

Author(s):

C. Vicente ◽

V. Babashov ◽

F. Husein ◽

F. Saad ◽

S. Naidoo ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Castration Resistant ◽

Previously Treated

PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY

Value in Health ◽

10.1016/j.jval.2019.09.1101 ◽

2019 ◽

Vol 22 ◽

pp. S611-S612

Author(s):

L. Silva Miguel ◽

A.T. Paquete ◽

M. Borges

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Androgen Deprivation ◽

Utility Analysis ◽

Neuroendocrine secretory profiles are not associated with treatment response to Lu-177-PSMA-617 radioligand therapy in patients with advanced metastatic castration-resistant prostate cancer

10.1055/s-0040-1708342 ◽

2020 ◽

Author(s):

T Derlin ◽

R Werner ◽

C Henkenberens ◽

TL Ross ◽

FM Bengel

Keyword(s):

Prostate Cancer ◽

Treatment Response ◽

Radioligand Therapy ◽

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

Endocrine Abstracts ◽

10.1530/endoabs.47.oc32 ◽

2016 ◽

Author(s):

Harshad R. Kulkarni ◽

Aviral Singh ◽

Christiane Schuchardt ◽

Karin Niepsch ◽

Richard P. Baum

Keyword(s):

Prostate Cancer ◽

Prostate Specific Membrane Antigen ◽

Radioligand Therapy ◽

Castration Resistant ◽

Specific Membrane

New combination therapies for castration-resistant prostate cancer

Oncology Abstracts ◽

10.1530/oncolabs.1.p031 ◽

2019 ◽

Author(s):

Mitchell G Lawrence ◽

Laura H Porter ◽

Daisuke Obinata ◽

Shahneen Sandhu ◽

Luke A Selth ◽

...

Keyword(s):

Prostate Cancer ◽

New Combination ◽

Combination Therapies ◽

The role of microbiota in driving castration-resistant prostate cancer

10.26226/morressier.5f69edb69b74b699bf38c5cf ◽

2020 ◽

Author(s):

Arianna Calcinotto

Keyword(s):

Prostate Cancer ◽